The presentation will be webcast and available following the live presentation. The webcast can be viewed at: http://wsw.com/webcast/rrshq27/eyes
Registration is mandatory. For more information about the conference or to schedule a one-on-one meeting, please contact your Rodman & Renshaw representative.
About the Argus II Retinal Prosthesis System
Second Sight's Argus II System provides electrical stimulation that
bypasses the defunct retinal cells and stimulates remaining viable cells
inducing visual perception in individuals with severe to profound
Retinitis Pigmentosa. The Argus II works by converting images captured
by a miniature video camera mounted on the patient's glasses into a
series of small electrical pulses, which are transmitted wirelessly to
an array of electrodes implanted on the surface of the retina. These
pulses stimulate the retina's remaining cells, intending to result in
the perception of patterns of light in the brain. The patient must learn
to interpret these visual patterns, having the potential to regain some
visual function. The Argus II was the first artificial retina to receive
widespread commercial approval, and is offered at approved centers in
About the Orion Visual Cortical Prosthesis System
Second Sight, the manufacturer of the Argus II Retinal Prosthesis System
(Argus II), has developed a new device, the Orion. A proof-of-concept
clinical trial demonstrating the viability of stimulation of the human
visual cortex with a commercially available device from a different
manufacturer began in Q4 2016 at
About Second Sight
Second Sight's mission is to develop, manufacture and market innovative
implantable visual prosthetics to enable blind individuals to achieve
greater independence. Second Sight has developed and now manufactures
and markets the Argus® II Retinal Prosthesis System. Enrollment has been
completed in a feasibility trial to test the safety and utility of the
Argus II in individuals with Dry Age-Related Macular Degeneration.
Second Sight is also developing the Orion™ Visual Cortical Prosthesis to
restore some vision to individuals who are blind due to causes other
than preventable or treatable conditions.
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange and Exchange Act of 1934, as amended, which are intended to be covered by the "safe harbor" created by those sections. All statements in this release that are not based on historical fact are "forward looking statements." These statements may be identified by words such as "estimates," "anticipates," "projects," "plans," or "planned," "seeks," "may," "will," "expects," "intends," "believes," "should" and similar expressions or the negative versions thereof and which also may be identified by their context. All statements that address operating performance or events or developments that Second Sight expects or anticipates will occur in the future, such as stated objectives or goals, or that are not otherwise historical facts, are forward-looking statements. While management has based any forward looking statements included in this release on its current expectations, the information on which such expectations were based may change. Forward-looking statements involve inherent risks and uncertainties which could cause actual results to differ materially from those in the forward-looking statements, as a result of various factors including those risks and uncertainties described in the Risk Factors and in Management's Discussion and Analysis of Financial Condition and Results of Operations sections of our Annual Report on Form 10-K as filed on March 16, 2017, and our other reports filed from time to time with the Securities and Exchange Commission. We urge you to consider those risks and uncertainties in evaluating our forward-looking statements. We caution readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Except as otherwise required by the federal securities laws, we disclaim any obligation or undertaking to publicly release any updates or revisions to any forward-looking statement contained herein (or elsewhere) to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.
News Provided by Acquire Media